Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

BMJ open·2026
Same author

ASO Visual Abstract: Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.

Annals of surgical oncology·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial.

Annals of surgery·2026
Same author

Understanding Physical Functioning in Patients with Sarcoma After Amputation: Using an International Classification of Functioning, Disability and Health (ICF) Approach.

Annals of surgical oncology·2026
Same journal

Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma.

Annals of surgical oncology·2026
Same journal

ASO Author Reflections: The Hidden Cost of Gastric Preservation During Cytoreductive Surgery for Pseudomyxoma Peritonei: Understanding the Functional Consequences of Extensive Perigastric Cytoreduction.

Annals of surgical oncology·2026
Same journal

Survival of Squamous Cell Carcinoma Versus Adenocarcinoma in Resected Stage I-III Non-small Cell Lung Cancer.

Annals of surgical oncology·2026
Same journal

ASO Visual Abstract: Quality, Reliability, and Viewer Engagement of YouTube Videos on Esophageal Cancer: A Cross-Sectional Study.

Annals of surgical oncology·2026
Same journal

ASO Visual Abstract: Implementing Paradigm-Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.

Annals of surgical oncology·2026
Same journal

Trends in Breast and Axillary Operations in Young Patients with Operable Breast Cancer from the National Cancer Database (NCDB): De-escalation of Axillary Surgery and Increased Use of Radiation.

Annals of surgical oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.2K

Sarcoma: Last Year's Practice Changing Papers.

Winan J van Houdt1, Alessandro Gronchi2

  • 1Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands. w.v.houdt@nki.nl.

Annals of Surgical Oncology
|December 8, 2024
PubMed
Summary
This summary is machine-generated.

Recent advancements in soft tissue sarcoma research offer improved treatment strategies. Key studies highlight new genetic insights, refined radiotherapy protocols, and effective systemic therapies for various sarcoma types.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.8K

Related Experiment Videos

Last Updated: Jun 5, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.8K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Genetics

Background:

  • Soft tissue sarcomas are a diverse group of cancers with varied histotypes, locations, and behaviors.
  • Recent research in 2023-2024 has significantly advanced our understanding of these complex diseases.

Purpose of the Study:

  • To summarize seven pivotal publications impacting surgical practice and future treatment of soft tissue sarcomas.
  • To highlight key findings that will guide clinical decision-making and patient care.

Main Methods:

  • Review and synthesis of major studies published in 2023-2024 concerning soft tissue sarcomas.
  • Focus on research with direct implications for patient management and treatment strategies.

Main Results:

  • Enhanced understanding of sarcoma genetics for improved patient counseling and screening.
  • Clarified role of radiotherapy in retroperitoneal liposarcoma and introduced hypofractionated radiotherapy for extremity sarcomas.
  • Demonstrated improved outcomes for retroperitoneal sarcoma patients treated in high-volume centers.
  • Shift in desmoid tumor treatment paradigm towards systemic therapy with nirogacestat.
  • Positive Phase 3 trials showing improved progression-free survival with doxorubicin/trabectedin for leiomyosarcoma and improved disease-free survival with neoadjuvant/adjuvant pembrolizumab for localized sarcomas.

Conclusions:

  • Ongoing research continually refines soft tissue sarcoma management.
  • Emerging data provides better guidance for optimizing treatment strategies and improving patient outcomes.